Terms: = Bone cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
7 results:
1. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia.
Thomé CH; Ferreira GA; Pereira-Martins DA; Dos Santos GA; Ortiz CA; de Souza LEB; Sobral LM; Silva CLA; Scheucher PS; Gil CD; Leopoldino AM; Silveira DRA; Coelho-Silva JL; Traina F; Koury LC; Melo RAM; Bittencourt R; Pagnano K; Pasquini R; Nunes EC; Fagundes EM; Gloria ABF; Kerbauy FR; Chauffaille ML; Keating A; Tallman MS; Ribeiro RC; Dillon R; Ganser A; Löwenberg B; Valk P; Lo-Coco F; Sanz MA; Berliner N; Faça VM; Rego EM
Sci Rep; 2020 Jun; 10(1):10315. PubMed ID: 32587277
[TBL] [Abstract] [Full Text] [Related]
2. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
3. The clinical outcome of recurrent sacral chordoma with further surgical treatment.
Yang Y; Li Y; Liu W; Xu H; Niu X
Medicine (Baltimore); 2018 Dec; 97(52):e13730. PubMed ID: 30593146
[TBL] [Abstract] [Full Text] [Related]
4. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate cancer Pretreated With Docetaxel Chemotherapy: A Prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
5. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract] [Full Text] [Related]
6. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract] [Full Text] [Related]
7. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
